Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
USD 20.00
(+571.14%)
Based on the Reviva Pharmaceuticals Holdings Inc. stock forecast from 1 analysts, the average analyst target price for Reviva Pharmaceuticals Holdings Inc. is USD 20.00 over the next 12 months. Reviva Pharmaceuticals Holdings Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Reviva Pharmaceuticals Holdings Inc. is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Reviva Pharmaceuticals Holdings Inc.’s stock price was USD 2.98. Reviva Pharmaceuticals Holdings Inc.’s stock price has changed by -1.32% over the past week, -5.10% over the past month and -55.79% over the last year.
No recent analyst target price found for Reviva Pharmaceuticals Holdings Inc.
No recent average analyst rating found for Reviva Pharmaceuticals Holdings Inc.
Company Overview Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention"deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California. Read Less
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and i...Read More
Frequently Asked Questions About Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock
Based on ratings from 1 analysts Reviva Pharmaceuticals Holdings Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on RVPH's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for RVPH is USD 20.00 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 20.
Unfortunately we do not have enough data on RVPH's stock to indicate if its overvalued.
The last closing price of RVPH's stock was USD 2.98.
The most recent market capitalization for RVPH is USD 0.08B.
Based on targets from 1 analysts, the average taret price for RVPH is projected at USD 20.00 over the next 12 months.
This means that RVPH's stock price may go up by +571.14% over the next 12 months.
We can't find any ETFs which contains Reviva Pharmaceuticals Holdings Inc.'s stock.
As per our most recent records Reviva Pharmaceuticals Holdings Inc. has 0 Employees.
Reviva Pharmaceuticals Holdings Inc.'s registered address is 19925 Stevens Creek Boulevard, Cupertino, CA, United States, 95014.
You can get more information about it from Reviva Pharmaceuticals Holdings Inc.'s website at https://www.revivapharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RVPH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
